Mitsubishi UFJ Asset Management Co. Ltd. Acquires 9,578 Shares of Insulet Corporation $PODD

Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 7.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 134,357 shares of the medical instruments supplier’s stock after buying an additional 9,578 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.19% of Insulet worth $42,212,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Aviva PLC increased its position in shares of Insulet by 6.7% during the second quarter. Aviva PLC now owns 52,189 shares of the medical instruments supplier’s stock worth $16,397,000 after acquiring an additional 3,282 shares in the last quarter. Los Angeles Capital Management LLC lifted its position in Insulet by 518.0% in the 2nd quarter. Los Angeles Capital Management LLC now owns 167,231 shares of the medical instruments supplier’s stock valued at $52,541,000 after acquiring an additional 140,169 shares in the last quarter. Metis Global Partners LLC boosted its stake in Insulet by 6.4% during the 2nd quarter. Metis Global Partners LLC now owns 3,842 shares of the medical instruments supplier’s stock valued at $1,207,000 after purchasing an additional 230 shares during the last quarter. Penserra Capital Management LLC bought a new stake in Insulet during the 2nd quarter worth approximately $67,000. Finally, Golden State Wealth Management LLC increased its holdings in Insulet by 202.9% during the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock worth $32,000 after purchasing an additional 69 shares in the last quarter.

Insider Activity

In related news, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the sale, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Prem Singh sold 687 shares of the stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the transaction, the senior vice president owned 3,456 shares of the company’s stock, valued at $1,200,925.44. This represents a 16.58% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.39% of the company’s stock.

Analyst Ratings Changes

PODD has been the topic of a number of recent research reports. Wall Street Zen upgraded Insulet from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Royal Bank Of Canada increased their target price on shares of Insulet from $365.00 to $370.00 and gave the company an “outperform” rating in a report on Friday. UBS Group raised their price target on shares of Insulet from $320.00 to $355.00 and gave the company a “neutral” rating in a research report on Friday. Sanford C. Bernstein upped their price objective on shares of Insulet from $400.00 to $410.00 in a research report on Friday. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Insulet in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $374.10.

Insulet Price Performance

PODD opened at $320.35 on Tuesday. Insulet Corporation has a fifty-two week low of $230.05 and a fifty-two week high of $353.50. The firm has a 50-day moving average of $324.67 and a 200 day moving average of $310.73. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. The firm has a market cap of $22.55 billion, a P/E ratio of 97.37, a PEG ratio of 2.64 and a beta of 1.39.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm had revenue of $521.70 million for the quarter, compared to analysts’ expectations of $678.70 million. During the same period in the previous year, the company earned $1.08 earnings per share. The company’s quarterly revenue was up 29.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, research analysts expect that Insulet Corporation will post 3.92 EPS for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.